Filing Details

Accession Number:
0001714899-21-000085
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-23 20:25:01
Reporting Period:
2021-08-19
Accepted Time:
2021-08-23 20:25:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI Biological Products, (No Disgnostic Substances) (2836) 463872213
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724310 J. Ryan Watts C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-08-19 1,626 $49.38 2,177,450 No 4 S Indirect See footnote
Common Stock Disposition 2021-08-19 750 $49.97 2,176,700 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 151,691 Direct
Footnotes
  1. Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $48.81 to $49.80 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 5000 restricted stock units held by the Reporting Person.
  4. The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
  5. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.81 to $50.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  6. Includes 151,691 restricted stock units.